Three serum miRNAs as potential biomarkers for early diagnosis of cervical cancer

This study aimed to analyze the changes associated with serum miRNAs in patients with cervical intraepithelial neoplasia (CIN) and cervical cancer in predicting early-stage cervical cancer. A total of 229 serum samples were collected to extract miRNAs. The expression level of miR-146b-5p, miR-192-5p and miR-122-5p were determined via qRT-PCR (Quantitative Real-time PCR), and their relative expressions were calculated using the equation: 2−∆∆Ct. We observed significantly higher expression levels of serum miR-146b-5p, miR-192-5p and miR-122-5p in the cervical diseases (CIN and cervical cancer) compared with controls. The expression levels of serum miR-146b-5p, miR-192-5p and miR-122-5p in cervical cancer were significantly higher than in controls. The relative expressions of serum miR-146b-5p and miR-192-5p in CIN were significantly higher than controls. However, there was no difference in three miRNAs between CIN and cervical cancer. The relative expressions of serum miR-146b-5p in patients classified as FIGO (International Federation of Gynaecology and Obstetrics) stage I were significantly higher than in controls and CIN. The AUC (area under the ROC curve) of the three miRNAs combined with SCC (squamous cell carcinoma antigen) in diagnosing cervical cancer was 0.840, and the sensitivity and specificity were 0.632 and 0.957, respectively. Serum miR-146b-5p, miR-192-5p and miR-122-5p showed promising efficacy as noninvasive biomarkers to accurately diagnose cervical cancer and demonstrated certain early diagnostic values, especially miR-146b-5p and miR-192-5p. The combined use of the three serum miRNAs with SCC could further improve the diagnostic efficiency for cervical cancer.

Cervical cancer; Cervical intraepithelial neoplasia; miR-146b-5p; miR-192-5p; miR-122-5p

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68: 394–424.

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[3] de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International Journal of Cancer. 2017; 141: 664–670.

[4] Jardin F, Ruminy P, Penther D. MicroRNA and haematology. Hématologie. 2008; 14: 117–128.

[5] Slimene I, Messaoudi I, Elloumi A, lachiri Z. MicroRNA expression classification for human disease prediction. 2021 18th International Multi-Conference on Systems, Signals & Devices (SSD). IEEE: Monastir, Tunisia. 2021.

[6] Laffont B, Rayner KJ. MicroRNAs in the pathobiology and therapy of atherosclerosis. Canadian Journal of Cardiology. 2017; 33: 313–324.

[7] Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834–838.

[8] Nair VB, Manasa VG, Sinto MS, Jayasree K, James FV, Kannan S. Differential Expression of MicroRNAs in uterine cervical cancer and its implications in carcinogenesis; an integrative approach. International Journal of Gynecologic Cancer. 2018; 28: 553–562.

[9] Deftereos G, Corrie SR, Feng QH, Morihara J, Stern J, Hawes SE, et al. Expression of Mir-21 and Mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLOS ONE. 2011; 6: e28423.

[10] Zhang Z, Wang J, Li J, Wang X, Song W. MicroRNA-150 promotes cell proliferation, migration, and invasion of cervical cancer through targeting PDCD4. Biomedicine & Pharmacotherapy. 2018; 97: 511–517.

[11] Yang Y, Song K, Chang H, Chen L. Decreased expression of microRNA-126 is associated with poor prognosis in patients with cervical cancer. Diagnostic Pathology. 2014; 9: 220.

[12] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynecology & Obstetrics. 2009; 105: 103–104.

[13] Arocho A, Chen B, Ladanyi M, Pan Q. Validation of the 2−ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagnostic Molecular Pathology. 2006; 15: 56–61.

[14] Lucksom PG, Sherpa ML, Pradhan A, Lal S, Gupta C. Advances in HPV screening tests for cervical cancer—a review. The Journal of Obstetrics and Gynecology of India. 2022; 72: 13–18.

[15] Gopalani SV, Janitz AE, Campbell JE. Cervical cancer incidence and mortality among non-hispanic African American and white women, United States, 1999–2015. Journal of the National Medical Association. 2020; 112: 632–638.

[16] Singh M, Jha RP, Shri N, Bhattacharyya K, Patel P, Dhamnetiya D. Secular trends in incidence and mortality of cervical cancer in India and its states, 1990–2019: data from the Global Burden of Disease 2019 Study. BMC Cancer. 2022; 22: 149.

[17] Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Research. 2009; 19: 92–105.

[18] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215–233.

[19] Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005; 11: 1753–1761.

[20] Ha M, Kim VN. Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology. 2014; 15: 509–524.

[21] Zhao C, Sun G, Li S, Shi Y. A feedback regulatory loop involving microRNA-9 and nuclear receptor TLX in neural stem cell fate determination. Nature Structural & Molecular Biology. 2009; 16: 365–371.

[22] Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008; 7: 759–764.

[23] Liao J, Liu R, Shi Y, Yin L, Pu Y. Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. International Journal of Oncology. 2016; 48: 2567–2579.

[24] Ma Y, Zhang P, Wang F, Zhang H, Yang Y, Shi C, et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nature Communications 2012; 3: 1291.

[25] Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine. 2011; 17: 1101–1108.

[26] Veryaskina YA, Titov SE, Zhimulev IF. Reference genes for qPCR-Based miRNA expression profiling in 14 human tissues. Medical Principles and Practice. 2022; 31: 322–332.

[27] Du W, Huo ZR, Liang CC, Tao S-C, Sun YP. MicroRNA—new approach to diagnosis, treatment and prognosis prediction of breast cancer. Journal of Shanghai Jiao Tong University. 2013; 33: 510–515.

[28] Jiang L, Zhu Z, He C. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer. Future Oncology. 2016; 12: 1105–1115.

[29] Zhuang Z, Sun C, Gong H. High serum miR-484 expression is associated with the diagnosis and prognosis of patients with non-small cell lung cancer. Experimental and therapeutic medicine 2019; 18: 4095–4102.

[30] Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G, et al. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. Journal of Surgical Oncology. 2013; 107: 767–771.

[31] Ma R, Zhao M, Zou X, Zhou J, Bai Z. MicroRNA polymorphism: a target for diagnosis and prognosis of hepatocellular carcinoma? Oncology Letters 2021; 21: 324.

[32] Bonfrate L, Altomare DF, Di Lena M, Travaglio E, Rotelli MT, De Luca A, et al. MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. Journal of Gastrointestinal and Liver Diseases. 2013; 22: 311–320.

[33] Shen C, Yang H, Liu H, Wang X, Zhang Y, Xu R. Inhibitory effect and mechanisms of microRNA-146b-5p on the proliferation and metastatic potential of Caski human cervical cancer cells. Molecular Medicine Reports. 2015; 11: 3955–3961.

[34] Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Jaworski C, Duncan T, et al. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment epithelial cells by interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma. Molecular Vision. 2013; 19: 737–750.

[35] Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Molecular Medicine. 2011; 3: 279–290.

[36] Lin F, Wang X, Jie Z, Hong X, Li X, Wang M, et al. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. Journal of Huazhong University of Science and Technology. 2011; 31: 509–514.

[37] Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang X, et al. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cellular Physiology and Biochemistry. 2015; 35: 71–82.

[38] Dong RF, Zhuang YJ, Wang Y, Zhang ZY, Xu XZ, Mao YR, et al. Tumor suppressor miR-192-5p targets TRPM7 and inhibits proliferation and invasion in cervical cancer. The Kaohsiung Journal of Medical Sciences. 2021; 37: 699–708.

[39] Huang YL, Li XH, Ma H, Yue HY, Hu XY. Metabolites of intestinal microflora upregulate miR-192-5p to suppress proliferation of colon cancer cells via RhoA-ROCK-LIMK2 pathway. European Review for Medical and Pharmacological Sciences. 2020; 24: 1794–1806.

[40] Flammang I, Reese M, Yang Z, Eble JA, Dhayat SA. Tumor-suppressive miR-192-5p has prognostic value in pancreatic ductal adenocarcinoma. Cancers. 2020; 12: 1693.

[41] Feng S, Cong S, Zhang X, Bao X, Wang W, Li H, et al. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Research. 2011; 39: 6669–6678.

[42] Farzanehpour M, Mozhgani S, Jalilvand S, Faghihloo E, Akhavan S, Salimi V, et al. Serum and tissue miRNAs: potential biomarkers for the diagnosis of cervical cancer. Virology Journal. 2019; 16: 116.

[43] Yang Y, Liu Y, Liu W, Li C, Liu Y, Hu W, et al. MiR-122 inhibits the cervical cancer development by targeting the oncogene RAD21. Biochemical Genetics. 2022; 60: 303–314.

[44] He J, Ji Y, Li A, Zhang Q, Song W, Li Y, et al. MiR-122 directly inhibits human papillomavirus E6 gene and enhances interferon signaling through blocking suppressor of cytokine signaling 1 in SiHa cells. PLOS ONE. 2014; 9: e108410.

[45] Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, et al. MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biology & Therapy. 2018; 19: 427–435.

[46] Ma J, Li T, Han X, Yuan H. Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 2018; 144: 205–214.

[47] Li J, Zhao R, Fang R, Wang J. miR-122-5p inhibits the proliferation of melanoma cells by targeting NOP14. Journal of Southern Medical University. 2018; 38: 1360–1365. (In Chinese)

[48] Ergün S, Ulasli M, Igci YZ, Igci M, Kırkbes S, Borazan E, et al. The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Molecular Biology Reports. 2015; 42: 497–505.

[49] Jia W, Wu Y, Zhang Q, Gao GE, Zhang C, Xiang Y. Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Molecular and Clinical Oncology. 2015; 3: 851–858.